When a novel respiratory pathogen emerges, clinicians face an immediate dilemma regarding patients on chronic medications. If a drug interacts with the biological pathways the virus exploits, does continuing that treatment put the patient at risk? Conversely, does abruptly stopping it destabilize the patient's underlying health, making them more vulnerable to severe infection?
This research direction focuses on resolving these clinical uncertainties. By combining large-scale epidemiological data, target trial emulations, and systematic reviews, researchers have evaluated whether common medications exacerbate, remain neutral to, or mitigate outcomes in acute viral infections. The core insight of this field is that real-world physiological homeostasis usually outweighs theoretical cellular risks, and that apparent drug toxicities are frequently confounded by the severity of the underlying disease.
The RAAS Dilemma: Receptor Upregulation vs. Homeostatic Control
The clearest example of this clinical tension occurred with Renin-Angiotensin-Aldosterone System (RAAS) inhibitors, such as ACE inhibitors (ACEIs) and Angiotensin Receptor Blockers (ARBs). These are foundational therapies for hypertension and heart failure. However, because the SARS-CoV-2 virus utilizes the cellular receptor ACE2 to enter host cells, a major theoretical concern arose: could these medications upregulate ACE2 expression, effectively opening more doors for the virus and increasing viral load?
To explore the mechanics of this pathway, Ji et al. utilized knowledge-mining technology to map host pathological changes. They suggested that viral binding actually causes a severe RAS imbalance, hinting that ARBs might paradoxically protect patients by stabilizing this pathway and preventing subsequent cytokine storms.
[Chronic RAAS Inhibitor Use]
│
├─► Theoretical Risk: Upregulates ACE2 ──► Increases Viral Entry?
│
└─► Clinical Reality: Stabilizes RAS ────► Prevents Cytokine Storm & Maintains BP Control
Large-scale epidemiological studies rapidly moved to test these competing hypotheses in human cohorts. Hippisley–Cox et al. analyzed a massive cohort of 8.3 million people, demonstrating that the prescription of ACEIs or ARBs was not linked to an increased risk of severe disease requiring intensive care. In fact, they observed a reduced risk of testing positive for the virus entirely.
Supporting this, Ran et al. evaluated hypertensive patients and found that ARB use did not increase adverse clinical outcomes, but was instead associated with a lower risk of ICU admission. The authors emphasized that poor blood pressure control and high blood pressure variability were the true predictors of severe outcomes, meaning that maintaining chronic therapy was vital. This was further validated by Chouchana et al. in a retrospective study of over 8,000 hospitalized patients, which confirmed that RAAS inhibitors do not increase mortality risk. To untangle higher-order interactions, Platt et al. applied topological data analysis to metabolic syndrome conditions, confirming that RAAS-targeted hypertension therapies offered a protective effect compared to non-RAAS alternatives by mitigating systemic metabolic risks.
However, the literature also highlights the complexity of observational data. Tse et al. found an independent correlation between RAAS inhibitor use and an increased likelihood of testing positive and experiencing severe outcomes. This conflicting finding underscores why the field prioritizes massive, propensity-matched cohorts: because cardiovascular disease itself is a major risk factor for severe viral infections, separating the effect of the drug from the effect of the underlying condition requires meticulous statistical adjustment.
Disentangling Drug Toxicity from Disease Severity
A parallel challenge in this research area is determining whether an adverse event observed during acute treatment is caused by the drug or is simply a manifestation of a severe infection.
This dynamic is illustrated by investigations into the antiviral drug remdesivir. Because acute kidney injury (AKI) is a frequent complication in severe viral infections, early observations of kidney damage in patients receiving remdesivir raised concerns about potential drug-induced nephrotoxicity.
To resolve this, two separate systematic reviews by Xu et al. and Xu et al. pooled data from thousands of hospitalized patients. The authors established that remdesivir treatment does not significantly increase the risk of AKI. Instead, the incidence of kidney damage was tightly coupled with patient age and baseline disease severity.
The intuition here is a classic case of confounding by indication: sicker patients are more likely to receive aggressive antiviral therapy, and sicker patients are also more likely to experience multi-organ failure, including AKI. By comparing treated and untreated cohorts with similar baseline risks, the researchers demonstrated medication-outcome neutrality regarding renal health.
The Reassurance of Medication-Outcome Neutrality
For many widely used over-the-counter and maintenance medications, the primary goal of this research direction has been to establish safety through neutrality, debunking early alarmist hypotheses driven by isolated in vitro observations.
- NSAIDs and Paracetamol: Early in the COVID-19 pandemic, concerns emerged that non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen might worsen respiratory symptoms or alter viral receptor expression. Reese et al. addressed this by leveraging a 38-center retrospective cohort study of nearly 40,000 propensity-matched patients, finding absolutely no correlation between NSAID use and increased disease severity, mortality, or kidney failure. Similarly, Baldia et al. focused on high-risk elderly patients (aged 70+) in intensive care, proving that prior paracetamol intake for symptom management was entirely neutral and did not interfere with short- or long-term survival.
- Acid Suppressants: Because proton pump inhibitors (PPIs) and H2 receptor antagonists (H2RAs) alter gastric acid and had previously been associated with an increased risk of other respiratory infections, their safety was questioned. However, Zhang et al. found no significant association between chronic acid suppression and infection risk, clarifying a vital baseline for patients managing gastrointestinal conditions.
- Alpha-1 Blockers and Corticosteroids: Researchers also investigated whether drugs with systemic anti-inflammatory properties could be repurposed to prevent cytokine storms. Nishimura et al. conducted an international cohort study on alpha-1 blockers (commonly prescribed for benign prostatic hyperplasia), but found no significant association with reduced hospitalization or ICU admission, challenging the inflammation-mitigation hypothesis for this drug class. Meanwhile, Aveyard et al. examined inhaled corticosteroids (ICS) in patients with pre-existing respiratory diseases, balancing the theoretical risk of local immunosuppression against the benefit of airway stability, ultimately showing that the overall risk of death remained low.
Unexpected Off-Target Protection
While establishing neutrality is a victory for patient safety, this line of research occasionally uncovers unexpected protective benefits where a drug's secondary mechanism helps defend the host.
A clear example of this is found in metabolic therapies. Yu et al. conducted a meta-analysis of randomized controlled trials involving GLP-1 receptor agonists (GLP-1RAs), which are typically prescribed for type 2 diabetes and weight management. The authors discovered a statistically significant 14% reduction in the overall incidence of respiratory illnesses, specifically pulmonary edema and bronchitis.
This suggests that certain chronic medications do more than just manage their primary target condition; they can exert systemic, off-target anti-inflammatory or physiological effects that actively protect vulnerable organ systems during an acute viral challenge.
Key Foundational Work
Risk of severe COVID-19 disease with ACE inhibitors and angiotensin receptor blockers: cohort study including 8.3 million people (2020) — contributed 6 concept elements to this direction.
Relationship between angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and COVID-19 incidence or severe disease (2021) — contributed 3 concept elements to this direction.
Case–control study of the association of chronic acid suppression and social determinants of health with COVID-19 infection (2021) — contributed 3 concept elements to this direction.